Abramson Cancer Center at Penn Medicine: Lymphoma trials

The registry lists 13 Lymphoma studies with Abramson Cancer Center at Penn Medicine as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 6Phase 2 8No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pilot Study of an NTproBNP Guided Strategy of CardioprotectionCompletedNCT04737265Phase 1/2Results posted
• Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERSTerminatedNCT03495713Phase 2Results posted
• Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory LymphomasCompletedNCT02650999Phase 1/2Results posted
• Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma PatientsCompletedNCT01994850Phase 1/2Results posted
• Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)CompletedNCT01676831Phase 1/2Results posted
• Maintenance Lenalidomide in LymphomaCompletedNCT01575860Phase 1/2Results posted
• Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)CompletedNCT01004718Not applicableResults posted
• Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell LymphomasCompletedNCT00783367Phase 2Results posted
• Cardiovascular Effects of CART Cell TherapyCompletedNCT04026737
• Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell LymphomasWithdrawnNCT03586024Phase 1/2
• Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on LenalidomideTerminatedNCT03065790
• FDG-PET/CT Imaging as Early Predictor of DPCompletedNCT02476734
• DIBH Proton PlanningCompletedNCT01386697